Chengdu
China
Sichuan University - Department of Biotherapy
neoadjuvant immunotherapy, camrelizumab, esophageal squamous cell carcinoma, clinical efficacy, immune response
triple negative breast cancer, immune-related gene, nomogram, risk stratification